Correlations of high miRNA expressions with traditional proteins and prognosis of breast cancer

Author:

Chen Jianrong1,Zhang Haiyong1,Li Xiufang1,Hu Mengjun1

Affiliation:

1. 1 Department of Pathology , Zhuji People’s Hospital of Zhejiang Province , Zhuji, Zhejiang Province , China

Abstract

Abstract Background In this study, we aimed to analyze the correlations of high expressions of micro ribonucleic acids (miRNAs) with traditional proteins and prognosis of breast cancer. Methods The clinical data of 60 breast cancer patients treated from August 2018 to July 2019 were retrospectively analyzed. All the patients received radical mastectomy combined with postoperative adjuvant chemoradiotherapy and were followed up for 3 years after treatment. The 3-year survival was recorded. The surviving patients were included in a good prognosis group, and the deceased ones were assigned to a poor prognosis group. The levels of miRNAs (miR-182, miR-155, and miR-217) and traditional breast cancer proteins [estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (CerbB-2/HER-2), and cell proliferation factor-67 (Ki-67)] were measured. Receiver operating characteristic (ROC) curve was plotted to investigate the predictive value of miRNA levels for poor prognosis. Results The relative expressions of miR-182, miR-155 and miR-217 were negatively correlated with ER and PR (r<0, P<0.05), but positively correlated with positive Ki-67 expression (r>0, P<0.05). High relative expressions of miR-182, miR-155 and miR-217 and positive Ki-67 expression were risk factors for poor prognosis, and the positive expressions of ER and PR were protective factors (OR<1, P<0.05). The areas under the curves of the relative expressions of miR-182, miR-155 and miR-217 and combined detection for predicting poor prognosis all exceeded 0.70. The combined detection had the highest predictive value. Conclusions The high expressions of miR-182, miR-155 and miR-217 are correlated with the expressions of traditional breast cancer proteins ER, PR, and Ki-67, and may predict the prognosis of breast cancer patients.

Publisher

Walter de Gruyter GmbH

Reference28 articles.

1. Liu L, Yang Y, Guo Q, Ren B, Peng Q, Zou L, et al. Comparing hypofractionated to conventional fractionated radiotherapy in postmastectomy breast cancer: a meta-analysis and systematic review. Radiat Oncol. 2020;15(1):17. DOI: 10.1186/s13014-020-1463-1

2. Kadam SS, Tripathi P, Jagtap R, Kapoor R, Kadam T, Bhandarkar P, et al. Modified Radical Mastectomy vs Breast-Conserving Surgery: Current Clinical Practice in Women with Early Stage Breast Cancer at a Corporate Tertiary Cancer Center in India. Indian J Surg Oncol. 2022;13(2):322-8. DOI: 10.1007/s13193-021-01457-8

3. Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, et al Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol. 2021;32(8):1015-24. DOI: 10.1016/j.annonc.2021.05.353

4. Horisawa N, Adachi Y, Takatsuka D, Nozawa K, Endo Y, Ozaki Y, et al. The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status. Breast Cancer. 2022;29(2):234-41. DOI: 10.1007/s12282-021-01303-3

5. Fleming GF, Pagani O, Regan MM, Walley BA, Francis PA. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2022;33(6):658. DOI: 10.1016/j. annonc.2022.03.003

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3